Until recently, indications for standard-of-care molecular testing in colorectal carcinomas (CRC) included testing for exon 2 KRAS mutational status as a predictor of response to cetuximab (Erbitux; Merck KGaA) and to panitumumab (Vectibix; Amgen Inc.)[5]. Here, KRAS is linked to colorectal carcinoma.